Resistance mechanisms of tumour cells to EGFR inhibitors.

Abstract

In spite of the overexpression and efficient inhibition of epidermal growth factor receptor (EGFR), resistance to EGFR inhibitors, monoclonal antibodies and tyrosine kinase inhibitors may occur. Understanding the molecular mechanisms affecting cancer cell sensitivity or resistance to EGFR inhibitors may be of help in deciding on treatment and in new translational studies. This review will focus on the most relevant mechanisms contributing to the acquisition of sensitivity/resistance to EGFR inhibitors.

Cite this paper

@article{Morgillo2009ResistanceMO, title={Resistance mechanisms of tumour cells to EGFR inhibitors.}, author={Floriana Morgillo and Flavia Cantile and Morena Fasano and Teresa Troiani and Erika Martinelli and Fortunato Ciardiello}, journal={Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico}, year={2009}, volume={11 5}, pages={270-5} }